<?xml version="1.0" encoding="UTF-8"?>
<p>In Japan, favipiravir (
 <xref ref-type="fig" rid="F3">Figure 3</xref>) was primarily developed and approved as an anti-influenza drug (Shiraki and Daikoku, 
 <xref rid="B166" ref-type="bibr">2020</xref>; Wang et al., 
 <xref rid="B186" ref-type="bibr">2020b</xref>). This antiviral drug has a wide range of activities against various RNA viruses including rhinovirus, respiratory syncytial virus (RSV), and influenza. Former studies revealed that favipiravir was successfully used to treat infections associated with rabies, Lassa virus, and Ebola virus (Shiraki and Daikoku, 
 <xref rid="B166" ref-type="bibr">2020</xref>). Furthermore, favipiravir was also found to be effective to treat severe fever with thrombocytopenia syndrome (Shiraki and Daikoku, 
 <xref rid="B166" ref-type="bibr">2020</xref>). Nevertheless, favipiravir was found to be ineffective against DNA viruses.
</p>
